Board and Management
Board of Directors
Mr. Jørgensen holds a BA in Finance and Administration from Copenhagen Business School. He has previously been CEO of Dako AS, heading this global supplier of research reagents and diagnostic`s between 1989 and 1999. Other positions Mr. Jørgensen has held include CEO for Karo Bio, CEO for Affibody AB and most recently CEO and President of Biotage AB. He is also board member of Intervacc AB and Micropos Medical AB
Prof. Uhlén is a co-founder of Atlas Antibodies AB. He is a Professor of Biotechnology at the Royal Institute of Technology in Stockholm and Program Director of the Human Protein Atlas project. Prof. Uhlén is a member of the Board of Directors of Novozymes A/S, Affibody AB, ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB, and The Antibodypedia AB.
Ms. Trautner is Chairman of Viewcare International A/S and CentaFlow Holding A/S. She holds a BA in Marketing and Business Development from Copenhagen Business School and a BA in biotechnology. She has been CEO of EuroDiagnostica AB, Exec Vice President Sales & Marketing of Dako A/S, the global supplier of cancer research reagents and diagnostics. Other positions Ms. Trautner has held include Vice President, Global Sales & Marketing of AdvanDx A/S and AdvanDx Inc., General Manager of Life Technologies A/S and General Manager of Dräger Medical Scandinavia.
Dr. Ljungqvist is President and CEO of GE Nordics and CEO of Testa Center at GE Healthcare. She is also a board member of Genovis AB, Vinnova, SciLifeLab and SwedenBio. Previously she was head of R&D BioProcess GE Life Sciences at GE Healthcare. She holds a Ph.D. in Biochemistry from the Royal Institute of Technology in Stockholm. During 2007/2008 she was CEO of IMEA AB, a biotech company dedicated to developing Biopharmaceuticals. Prior to that, Dr. Ljungqvist headed a Biopharmceutical Contract Manufacturing Organization in Biovitrum during 2001-2007. Other positions include project management positions with Pharmacia Corp & Pharmacia & Upjohn.
Mr. Johansson is Senior Advisor at Patricia Industries Nordic. In 2006 Lennart join the Management Group of Investor AB and held different positions including Head of Business Development, Head of Operating Investments and Head of Financial Investments. Prior to joining Investor, Mr. Johansson spent 14 years in Atlas Copco whereof nine years in senior management roles in Sweden and abroad. He has also been the CEO for two different venture capital companies. Mr. Johansson serves on the boards of Hi3G, SOBI and Vectura. Among previous board seats are Gambro, Lindorff, Mölnlycke AB and SAAB AB. He holds a MBA from Stockholm School of Economics.
Åsa Riisberg is formerly a Partner and Member of the Extended Executive Committee at EQT Partners AB. She held various leadership roles during her 20 year tenure at EQT, including Global Head of Healthcare Sector, Member of the Partners Committee and various other roles. Prior to joining EQT, Mrs Riisberg was an Associate at Texas Pacific Group (UK) and an Analyst at Morgan Stanley (UK).
She currently holds board memberships in Vifor Pharma AG (Member of the Board and Chair of Audit Committee), Netcompany AS (Member of the Board and Chair of Audit Committee), F-Secure Oy, Bonnier Capital, Bonnier News, Cinder Invest and Dagens Nyheter.
She holds a M.Sc. in Financial Economics and Business Administration from Stockholm School of Economics.
Ms. Kores is Investment Professional at Patricia Industries. She is also board member at Doktor24 and chair at mumbaistockholm. Previously she was Board member at Memira, deputy board member at Aleris and analyst at Goldman Sachs.
Nille Klæbel joined Atlas Antibodies from her role as CEO Nordics at Philips. Nille has extensive experience working with product and commercialization strategies within the global medtech and pharmaceutical industry. She has held leadership roles in companies such as Novo Nordisk, Sanofi and GlaxoSmithKline. Nille holds a M.Sc. in Economics and Business Administration, International Marketing and Management from the Copenhagen Business School.
Prior to joining Atlas Antibodies as CFO in 2019, Mr. Skoglund served as a Deputy Director on the Atlas Antibodies board and held a position as Principal at Patricia Industries Nordic, which he joined in 2015. At Patricia Industries, he managed the European portfolio of financial investments and supported operating companies Mölnlycke and 3Scandinavia. Mr. Skoglund first joined the Investor AB group in 2012 and has since then focused on investments in life science, technology and medtech. Mr. Skoglund holds an M.Sc. in Accounting and Financial Management from the Stockholm School of Economics, partly completed at National University of Singapore and partly at Cornell University, New York.
Theis Kipling is the Chief Commercial Officer and heads up Commercial operations. He joined the company in 2020 and comes with extensive international leadership experience across companies such as Agilent and Lundbeck. Mr. Kipling previously held leadership positions within Global marketing as well as country management in Italy and Germany, Austria and Switzerland. He has a solid business and commercial track record but also a notable experience within finance obtained from his past career as controller. Mr. Kipling holds a M.Sc. within Business administration & management accounting from the Copenhagen Business School.
Dr. Kampf is a co-founder of Atlas Antibodies AB. Dr. Kampf is Associate Professor and has a Ph.D. in Cell Biology from Uppsala University. Over 10 years she played a key role in starting the Human Protein Atlas project, where she most recently held the position as Site Director for the Uppsala site, responsible for the immunohistochemical antibody validation. Prior to joining Atlas Antibodies, she has worked at Olink Proteomics AB and Affibody AB.
Kia Frenssen joined Atlas Antibodies in 2021. She has extensive experience from leading roles within Supply Chain, Production and Quality Assurance from Astra, AstraZeneca and APL, Apotek Produktion och Laboratorier AB.
Ms. Frenssen holds a M.Sc in Pharmacy.
Ms. Hjortsmark joined Atlas Antibodies in 2019. She has vast experience in leading marketing, product management and support teams in the Life Science industry.
Ms. Hjortsmark began her career in life sciences at Pharmacia Biotech (now Cytiva) in 1991 and has since then successfully held several key roles in marketing at Pyrosequencing (now Qiagen) Phadia (now Thermo Fisher Scientific) and most recently at Gyros Protein Technologies. Ms. Hjortsmark holds a BSc. in Molecular Biology.
Filippa Stenberg is on a one-year secondment from her role as Investment Manager at Investor AB, where she is responsible for Investor’s listed Healthcare companies. Prior to joining Investor in 2012, she worked as an analyst at Swedbank Equity Capital Markets for a couple of years. Filippa is also a member of the Board of Directors of the listed biopharmaceutical company Swedish Orphan Biovitrum (Sobi). She holds a M.Sc. in Accounting and Financial Management from Stockholm School of Economics.